Adocia Reacquires Exclusive Development Rights to Ultra-Fast Acting Insulin Analog
News Jul 30, 2013
Adocia has announced that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone® technology for the formulation of fast acting insulin analog formulated with the BioChaperone® technology. Consequently, the two companies have terminated the collaboration.
“We intend to pursue more actively this project by ourselves as the phase I clinical trial met the predefined clinical endpoints, hence confirming the great potential of our BioChaperone® technology” said Gerard Soula, President and CEO, Adocia.
“Our plan is to test a BioChaperone® insulin analog formulation on type I diabetic patients. For this, we intend to conduct a clinical trial, before year end in Germany, on one or more formulations of insulin analog. This trial will be carried out in parallel to the one already scheduled with HinsBet®, our formulation of human insulin” said Olivier Soula, deputy general manager and director R&D, Adocia.
The company has a strong financial position enabling the development of this priority project at its own expense.
Next scheduled events
September 5, 2013: Publication of mid-year financial statements as of June 30, 2013.
September 6, 2013: Presentation meeting to investors (SFAF).
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
CBD Significantly Reduces Seizures in Patients with Severe Form of EpilepsyNews
Large-scale clinical trial finds cannabidiol can dramatically reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018